RxDoctor Payments Data

Stacie Ly, MD

Internal Medicine · Carlsbad, CANPI 1114028669

Payments from drug & device makers

$3,015in general payments, 2019–2025

Across 59 payments — averaging $51.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$419
  • AbbVie$263
  • Novo Nordisk$254
  • GSK$251
  • Abbott$242
  • plus $425 from 6 others

What the payments were for

  • Speaking & faculty fees$1505%
  • Travel & lodging$20%
  • Food & beverage$2,86395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca16$1,160
Lilly USA, LLC15$419
AbbVie6$263
Novo Nordisk3$254
GSK5$251
Abbott4$242
Sanofi-aventis U.S. LLC1$150
Pfizer1$124
Astellas Pharma US Inc3$63
Merck3$56
Bayer1$16
Amgen1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,015 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$157,044
Medicare patients
371
Services billed
1,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$28,297
OzempicSemaglutide14$20,090
MounjaroTirzepatide11$10,832
Atorvastatin Calcium256$2,891
SynthroidLevothyroxine Sodium62$2,768
Levothyroxine Sodium211$2,372
Bupropion XlBupropion Hcl76$2,180
Rosuvastatin Calcium183$2,109
Valsartan64$2,058
Gabapentin87$1,555
PaxlovidNirmatrelvir/Ritonavir18$1,429
Losartan Potassium165$1,429
Metoprolol Succinate81$1,375
Amlodipine Besylate176$1,323
Potassium Chloride26$1,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$124$29,72643 claims
Novo NordiskOzempic$254$20,09014 claims
Lilly USA, LLCMounjaro$419$10,83211 claims
AbbVieSynthroid$263$2,76862 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →